| ENZY Stock | | | SEK 1.75 0.02 1.13% |
Chairman
Mr. Bengt Baron was Independent Chairman of the Board at Enzymatica AB since December 19, 2016. He is also Chairman of MIPS AB and Member of the board of Thule Group AB and 5653 Sweden AB. Bengt has previously been CEO of Cloetta AB and Leaf International B.V. He holds MA and MBA from University of California, Berkeley. since 2016.
| Age | 57 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 46 4 62 86 31 00 |
| Web | https://www.enzymatica.se |
Enzymatica Publ Management Efficiency
The company has return on total asset
(ROA) of
(0.1909) % which means that it has lost $0.1909 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(0.4032) %, meaning that it generated substantial loss on money invested by shareholders. Enzymatica Publ's management efficiency ratios could be used to measure how well Enzymatica Publ manages its routine affairs as well as how well it operates its assets and liabilities.
Enzymatica publ AB has accumulated 1.12
M in total debt with debt to equity ratio
(D/E) of 0.11, which may suggest the company is not taking enough advantage from borrowing. Enzymatica publ AB has a current ratio of 2.04, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Enzymatica Publ until it has trouble settling it off, either with new capital or with free cash flow. So, Enzymatica Publ's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Enzymatica publ AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Enzymatica to invest in growth at high rates of return. When we think about Enzymatica Publ's use of debt, we should always consider it together with cash and equity.
Similar Executives
Enzymatica AB, a life science company, develops and sells medical devices for infection-related diseases in Sweden and internationally. Enzymatica AB was incorporated in 2007 and is based in Lund, Sweden. Enzymatica operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 24 people. Enzymatica publ AB (ENZY) is traded on Stockholm Exchange in Sweden and employs 23 people.
Management Performance
Enzymatica publ AB Leadership Team
Elected by the shareholders, the Enzymatica Publ's board of directors comprises two types of representatives: Enzymatica Publ inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enzymatica. The board's role is to monitor Enzymatica Publ's management team and ensure that shareholders' interests are well served. Enzymatica Publ's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enzymatica Publ's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bengt Baron, Independent Chairman of the Board | |
| Mats Clarsund, Executive Vice President for Research and Development | |
| Stefan Olsson, Communication Mang | |
| Claus Egstrand, Chief Commercial Officer | |
| Ulf Blom, Executive Vice President Marketing and Operations | |
| Louise Nicolin, Director | |
| Anna Isaksson, Vice President Quality and Regulatory Management | |
| Therese Filmersson, Chief Financial Officer | |
| Marianne Alexandersson, Independent Director | |
| Gudmundur Palmason, Director | |
| Jorgen Rexo, Executive Vice President Legal, Director | |
| Mats Andersson, Director | |
| Fredrik Lindberg, Chief Executive Officer | |
| Johan Lindvall, Chief Operating Officer, Executive Vice President | |
Enzymatica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enzymatica Publ a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Enzymatica Stock Analysis
When running Enzymatica Publ's price analysis, check to
measure Enzymatica Publ's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enzymatica Publ is operating at the current time. Most of Enzymatica Publ's value examination focuses on studying past and present price action to
predict the probability of Enzymatica Publ's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enzymatica Publ's price. Additionally, you may evaluate how the addition of Enzymatica Publ to your portfolios can decrease your overall portfolio volatility.